78880-65-6

Usage

Primary Uses

Epilepsy, bipolar disorder, and trigeminal neuralgia treatment

Mechanism of Action

Stabilizes electrical activity in the brain, affects neurotransmitters and sodium channels

Drug Classification

Anticonvulsant and mood-stabilizing drug

Prescription Purpose

Control seizures, manage mood swings in bipolar disorder patients

Potential Side Effects

Dizziness, drowsiness, gastrointestinal disturbances

Monitoring Requirement

Blood levels to ensure therapeutic efficacy and minimize adverse effects risk

Administration Route

Oral

InChI:InChI=1/C15H10N2O/c16-10-17-13-7-3-1-5-11(13)9-15(18)12-6-2-4-8-14(12)17/h1-8H,9H2

Upstream product

• 110-80-5 2-ethoxy-ethanol 
• 78880-63-4 5-cyano-10-nitro-5H-dibenz[b,f]azepine 
• 7439-89-6 iron 
• 42787-75-7 5-cyanodibenzazepine 

Downstream Products

• 28721-07-5 oxcarbazepine 
• 391670-48-7 2-(5-oxo-6H-indolo[1,2-a]quinazolin-7-yl)acetic acid 

Relevant academic research and scientific papers

Iron-Catalyzed Wacker-type Oxidation of Olefins at Room Temperature with 1,3-Diketones or Neocuproine as Ligands**

Herein, we describe a convenient and general method for the oxidation of olefins to ketones using either tris(dibenzoylmethanato)iron(III) [Fe(dbm)3] or a combination of iron(II) chloride and neocuproine (2,9-dimethyl-1,10-phenanthroline) as catalysts and phenylsilane (PhSiH3) as additive. All reactions proceed efficiently at room temperature using air as sole oxidant. This transformation has been applied to a variety of substrates, is operationally simple, proceeds under mild reaction conditions, and shows a high functional-group tolerance. The ketones are formed smoothly in up to 97 % yield and with 100 % regioselectivity, while the corresponding alcohols were observed as by-products. Labeling experiments showed that an incorporated hydrogen atom originates from the phenylsilane. The oxygen atom of the ketone as well as of the alcohol derives from the ambient atmosphere.

5-CYANO-10-HYDROXY-10,11-DIHYDRO-5H-DIBENZ[B,F]AZEPINE, THE PROCESSES FOR ITS PREPARATION AND FOR ITS CONVERSION INTO 5-CARBAMOYL-10-OXO-10, 11-DIHYDRO-5H-DIBENZ[B,F]AZEPINE OR INTO 5-CARBAMOYL-5H-DIBENZ[B,F]AZEPINE

5-Cyano-10-Hydroxy-10,11-Dihydro-5H-Dibenzi[b,f]azepine and the process for its preparation.

5-Cyano-10-hydroxy-10,11-dihydro-5H-dibenz[b,f]azepine, processes for its preparation and for its conversion into 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine or into 5-carbamoyl-5H-dibenz[b,f]azepine

A process and intermediates useful for the preparation of carbamazepine and oxcarbamazepine are disclosed.

Process for the manufacture of 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,]azepine

The invention relates to a process for the manufacture of the known 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine of the formula III which is characterized in that, for example, 5-cyano-5H-dibenz[b,f]azepine of the formula I is nitrated to form 5-cyano-10-nitro-5H-dibenz[b,f]azepine of the formula II, this is subjected to hydrolysis, then reduction, then the reduction product contained in the reaction mixture is subjected to hydrolysis and the end product of the formula III is isolated in pure form. The process is illustrated by the following reaction scheme: STR1 The invention relates also to new intermediates produced in these reactions.